



Saskatchewan Immunization Manual Amendments June 2012

Instruction: Please remove and discard the corresponding pages in each chapter section and insert the amended pages as noted below in each corresponding chapter section dated **June 2012**.

Chapter 3 Informed Consent

- p. 7 (dated April 2012) Section 3.0 Step by Step Process for Obtaining Informed Consent
 - Step 4, 3rd bullet typo corrected to state, “...**demonstrate** understanding..”
- p. 9 (dated April 2012) Section 4.0 Checklist for Obtaining Informed Consent for a Vaccine Series
 - Point 3c vi amended to state, “Possible serious, severe or unusual adverse events and their frequency as noted in Appendix 3.2: *Relative Risk of Vaccine-Preventable Diseases and Immunizations*”.
- p. 11 (dated April 2012) Appendix 3.1 Recommended Immunization Websites, Books and Articles for Parents and Caregivers
 - New statement added to first paragraph: “Saskatchewan Public Health nurses are not affiliated with any vaccine manufacturers and can provide reliable immunization information for parents to make the best decisions for the health of their child.
 - CCIAP link updated as organization has changed their name to *Immunize Canada*.
 - New international resource links included.
- pp. 14, 16, 17 (dated April 2012) App. 3.2 Relative Risk of Vaccine-Preventable Diseases and Immunizations
 - Various typos corrected.

Chapter 5 Immunization Schedules

- Table of Contents 1st page (dated May 2012) Section 1.7 title updated as per bullet below.
- p. 8 (dated May 2012) Section 1.7 Recommended Immunization for Adults Who Completed a Primary Vaccine Series
 - Title now refers to recommended publicly funded immunizations.
 - New Td/Tdap bullet added: “A dose of Tdap should be offered to post-natal women, and parents and caregivers of infants less than 6 months of age who have not previously received an adult dose of Tdap”.
- p. 9 (dated May 2012) Section 1.8 Publicly Funded Vaccine Eligibility Criteria
 - 3rd main varicella bullet amended to state, “Susceptible individuals born between January 1, 2001-December 31, 2003 are only eligible for immunization in grade 6 or later”.

Chapter 6 Contraindications and Precautions

- p. 9 (Dated May 2012) Appendix 6.2: Selected Publicly Funded Biological Products That Contain Latex (Natural)
 - Menactra removed from table.



Chapter 7 Immunization of Special Populations

- Table of Contents 2nd page (dated May 2012) Section 3.4.1 and Appendix 7.6 titles updated as per bullets below.
- p. 31 (dated May 31) Section 3.2.1 Recommended Vaccines for Healthcare Workers and Healthcare Students
 - 1st bullet in HB row, last column amended to refer to section 3.2 for recommendations.
 - Last sentence in 2nd bullet in HB row, last column amended to state, “They must receive 2 doses of HBIg one month apart if exposed”.
- p. 34 (dated May 2012) Section 3.4.1 Recommended Vaccines for Individuals Recently New to Canada
 - Clarification of MMRV eligibility – now states susceptible eligible children.
 - Title changes
- p. 38 (dated May 2012) Appendix 7.1 Publicly Funded Vaccine Recommendations for Selected Special Populations
 - Vaccine header row from p. 37 carried over onto page 38.
- p. 40 Appendix 7.3 (dated May 2012)
 - Footnote 3 corrected to be noted as footnote 2.
- p. 43 (dated May 2012) Appendix 7.6 Immunization Schedule for Adult Post-Hematopoietic Stem Cell Transplant Recipients
 - Titre check schedules added
 - Title changes

Chapter 8 Administration of Biological Products

- 1st page of Table of Contents (dated April 2012)
 - Section 1.5 re-titled (refer to p. 7 below)
- p. 4 (dated April 2012) Section 1.3.3 Vials
 - Point 11 revised to stress single use/dose vials are for single patient use only.
 - Points 12 and 13 combined for formatting purposes.
- p. 7 (dated May 2012) 1.5 Publicly Funded Immunizations Following Non-Conforming Situations
 - Revision of section title to specify publicly funded immunizations context.
- p. 7 (dated May 2012) Section 1.5.1 Vaccines Given at Less than the Recommended Interval
 - 3rd bullet amended and differentiated into new 3rd and 4th bullets. 4th bullet notes that oral live vaccines can be given at any time before or after a live injectable or intranasal vaccine.
- p. 9 (dated April 2012) Sections 2.2 Injection Guidelines and 2.3 Anatomical Guidelines and Sites
 - Various bullet typos corrected.
- p. 10 (dated April 2012) Table 1: Intramuscular Injection Site, Needle Length and Total Site Volume per Age Group
 - Total site volume column numerical volumes amended to prevent medication errors as per current SRNA documentation standards.



Chapter 10 Biological Products

- MMRV and both MMR vaccines (all dated May 2012)
 - New **precaution** added: “Physician-diagnosed thrombocytopenia after first dose of a MMR-containing vaccine”.
 - Physician-diagnosed thrombocytopenia after first dose of a MMR-containing vaccine removed as a **contraindication** to both MMR vaccines.
- NeisVac-C (dated April 2012)
 - Contraindications row amended to state, “History of anaphylactic reaction to a previous dose of any meningococcal vaccine or to any component of NeisVac-C®”.
- Menactra (dated April 2012)
 - Point 3 updated to state, “In meningococcal A, C, Y or W-135 outbreak exposure situations, under the direction of an MHO, Menveo may be used in children as early as 2 months of age and in people over age 55. Refer to the Saskatchewan Communicable Disease Control Manual at <http://www.health.gov.sk.ca/communicable-disease-control-manual>”.
 - Latex removed as a contraindication.
- Menveo (page 1 of 2, dated April 2012)
 - Point 4 updated to state, “In meningococcal A, C, Y or W-135 outbreak exposure situations, under the direction of an MHO, Menveo may be used in children as early as 2 months of age and in people over age 55. Refer to the Saskatchewan Communicable Disease Control Manual at <http://www.health.gov.sk.ca/communicable-disease-control-manual>”.
- Immune Globulin Preparation Maximum Site Volume (table dated April 2012)
 - Ventrogluteal site removed as primary site from first 2 age groups.
 - Footnotes 1, 2 & 3 removed, as ventrogluteal site as preferential site for Ig product administration is not applicable to all age groups.

Chapter 11 Adverse Events Following Immunization

- p. 4 (dated April 2012) Section 2.5 Systemic Reactions
 - Final sentence in 3rd paragraph amended to state, “This vasovagal reaction must be distinguished from an immediate allergic reaction, and the health-care provider is required to report this to public health”.

Chapter 14 Appendices

- p. 18 (dated April 2012) Appendix 14.1 Glossary
 - Thimerosal definition corrected for clarity.
- p. 21 (dated May 2012) Appendix 14.3 Immunization fact Sheets
 - Dates updated as required.